Sectra AB Class B (SE:SECT.B)
:SECT.B
Want to see SE:SECT.B full AI Analyst Report?
Top Page
Sectra AB Class B
(SECT.B)
Select Model
Select Model
Rating:78Outperform
Price Target:
kr316.00
▲(26.20% Upside)
Action:Upgraded
Date:05/23/26
The score is primarily driven by strong financial performance (rapid TTM growth, solid margins, and very low leverage with high ROE). Technicals are supportive with an uptrend and positive momentum, though nearing overbought levels. Valuation is the main constraint due to the very high P/E and low dividend yield.
Positive Factors
Recurring, mission-critical revenue
Sectra's revenue base is anchored in multi-year contracts and recurring support/subscription fees for hospital imaging and secure communications. Those mission-critical deployments produce high customer retention, predictable recurring revenue and strong lifetime value, supporting durable cash flow and organic growth over multiple years.
Negative Factors
Margin and gross-profit volatility
Notable year-to-year swings in gross profit and margins suggest revenue mix, pricing, or project-recognition variability. Such volatility weakens earnings predictability and complicates capacity planning, making long-term margin guidance and cash flow forecasting less reliable for investors and management planning.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring, mission-critical revenue
Sectra's revenue base is anchored in multi-year contracts and recurring support/subscription fees for hospital imaging and secure communications. Those mission-critical deployments produce high customer retention, predictable recurring revenue and strong lifetime value, supporting durable cash flow and organic growth over multiple years.
Read all positive factors
Sectra AB Class B (SECT.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr53.54B
Dividend Yield0.43%
Average Volume (3M)138.54K
Price to Earnings (P/E)68.4
Beta (1Y)0.48
Revenue Growth6.16%
EPS Growth-9.00%
CountrySE
Employees1,234
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)2.79
Shares Outstanding182,017,440
10 Day Avg. Volume126,769
30 Day Avg. Volume138,545
Financial Highlights & Ratios
PEG Ratio3.22
Price to Book (P/B)29.81
Price to Sales (P/S)17.64
P/FCF Ratio70.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr210.00Price Target Upside-16.13% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)3.68
Revenue Forecast (FY)kr3.79B
Sectra AB Class B Business Overview & Revenue Model
Company Description
Sectra AB Class B (SECT.B) is a Swedish company specializing in medical technology and cybersecurity solutions. It operates primarily in the healthcare sector, offering products and services that enhance medical imaging, radiology, and pathology. ...
How the Company Makes Money
Sectra primarily makes money through two main business areas: medical imaging IT and secure communications/cybersecurity. In medical imaging, it generates revenue by licensing and delivering software platforms (e.g., PACS/RIS and enterprise imagin...
Sectra AB Class B Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
80
Positive
| Breakdown | TTM | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.42B | 3.24B | 2.96B | 2.35B | 1.95B | 1.63B |
| Gross Profit | 1.87B | 543.41M | 557.55M | 488.91M | 1.71B | 1.48B |
| EBITDA | 784.05M | 795.35M | 615.06M | 538.55M | 477.28M | 429.01M |
| Net Income | 537.49M | 563.37M | 428.39M | 374.96M | 314.79M | 275.51M |
Balance Sheet | ||||||
| Total Assets | 4.05B | 3.76B | 3.21B | 2.74B | 2.19B | 1.65B |
| Cash, Cash Equivalents and Short-Term Investments | 1.35B | 1.34B | 804.64M | 945.24M | 808.77M | 454.85M |
| Total Debt | 109.51M | 87.46M | 31.79M | 82.26M | 62.62M | 73.45M |
| Total Liabilities | 2.12B | 1.84B | 1.64B | 1.44B | 1.11B | 756.33M |
| Stockholders Equity | 1.93B | 1.92B | 1.57B | 1.30B | 1.08B | 895.62M |
Cash Flow | ||||||
| Free Cash Flow | 727.41M | 812.37M | 75.58M | 347.70M | 542.55M | 304.53M |
| Operating Cash Flow | 799.99M | 922.36M | 326.33M | 440.49M | 616.92M | 372.19M |
| Investing Cash Flow | -136.29M | -113.86M | -130.74M | -212.79M | -68.35M | -66.82M |
| Financing Cash Flow | -448.49M | -251.88M | -222.20M | -219.29M | -198.75M | -198.69M |
Sectra AB Class B Technical Analysis
Positive
250.40
Price Trends
247.06
Positive
229.83
Positive
268.46
Positive
Market Momentum
6.51
Negative
70.11
Negative
87.91
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SECT.B, the sentiment is Positive. The current price of 250.4 is below the 20-day moving average (MA) of 262.79, above the 50-day MA of 247.06, and below the 200-day MA of 268.46, indicating a bullish trend. The MACD of 6.51 indicates Negative momentum. The RSI at 70.11 is Negative, neither overbought nor oversold. The STOCH value of 87.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SECT.B.
Sectra AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | kr53.54B | 68.38 | 27.98% | 0.43% | 6.16% | -9.00% | |
73 Outperform | kr9.23B | 49.68 | 1.20% | ― | -2.39% | -46.09% | |
72 Outperform | kr2.97B | 40.70 | 17.89% | 1.61% | -2.32% | -11.87% | |
69 Neutral | kr53.52B | 32.02 | 6.91% | 2.16% | -4.14% | 59.50% | |
58 Neutral | kr14.68B | 31.59 | 3.34% | 0.80% | -5.68% | -1106.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr1.34B | -2.24 | -50.36% | ― | -24.97% | -366.73% |
* Healthcare Sector Average
SE:SECT.B
Sectra AB Class B
276.80
-34.19
-10.99%
SE:GETI.B
Getinge
196.25
13.98
7.67%
SE:VITR
Vitrolife AB
106.80
-45.63
-29.94%
SE:BICO
BICO Group AB Class B
18.82
-17.62
-48.35%
SE:CEVI
CellaVision AB
122.00
-68.37
-35.91%
SE:XVIVO
Xvivo Perfusion AB
294.40
-23.40
-7.36%
Sectra AB Class B Corporate Events
Sectra boosts cloud-driven recurring revenue as orders surge in nine-month 2025/2026 report
Mar 6, 2026
Sectra reported strong demand in its nine-month 2025/2026 interim period, highlighted by a 4.2% increase in contracted order bookings to SEK 6.05 billion and an 18.5% rise in recurring revenue, driven by a 57.5% surge in cloud recurring revenue. N...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.